Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrence
Open Access
- 1 July 2017
- journal article
- review article
- Published by Taylor & Francis Ltd in Breast Cancer: Targets and Therapy
- Vol. ume 9, 461-471
- https://doi.org/10.2147/bctt.s111098
Abstract
In the last decades, in addition to conventional imaging techniques and magnetic resonance imaging (MRI), 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) has been shown to be relevant in the detection and management of breast cancer recurrence in doubtful cases in selected groups of patients. While there are no conclusive data indicating that imaging tests, including FDG PET/CT, produce a survival benefit in asymptomatic patients, FDG PET/CT can be useful for identifying the site of relapse when traditional imaging methods are equivocal or conflicting and for identifying or confirming isolated loco-regional relapse or isolated metastatic lesions. The present narrative review deals with the potential role of FDG PET in these clinical settings by comparing its accuracy and impact with conventional imaging modalities such as CT, ultrasound, bone scan, 18F-sodium fluoride PET/CT (18F-NaF PET/CT) as well as MRI. Patient-focused perspectives in terms of patients’ satisfaction and acceptability are also discussed.Keywords
This publication has 83 references indexed in Scilit:
- 18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysisBreast Cancer Research, 2017
- Follow-up of patients with early breast cancer: Is it time to rewrite the story?Critical Reviews in Oncology/Hematology, 2014
- Contrast-enhanced [18 F] fluorodeoxyglucose-positron emission tomography/computed tomography in clinical oncology: tumor-, site-, and question-based comparison with standard positron emission tomography/computed tomographyCancer Imaging, 2014
- 18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTOJournal of Nuclear Medicine, 2013
- Estrogen receptor‐positive/human epidermal growth factor receptor 2‐negative breast tumorsCancer, 2013
- Tumor Marker–Guided PET in Breast Cancer Patients—A Recipe for a Perfect WeddingClinical Nuclear Medicine, 2012
- The detection of recurrent breast cancer in patients with a history of breast cancer surgery: comparison of clinical breast examination, mammography and ultrasonographyActa Radiologica, 2011
- Survivorship: Adult Cancer SurvivorsPrimary Care: Clinics in Office Practice, 2009
- US Surveillance of Regional Lymph Node Recurrence after Breast Cancer SurgeryRadiology, 2009
- Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancerAnnals of Oncology, 2008